Bleeding Disorders Treatment Market Size To Hit USD 35.17 Billion By 2032 – SNS Insider

(MENAFN- GlobeNewsWire - Nasdaq) Bleeding Disorders treatmentmarket Growth is Driven by Rising Prevalence of Hemophilia and Advancements in Treatment Options

Pune, March 04, 2025 (GLOBE NEWSWIRE) -- Bleeding Disorders Treatment Market Size & Growth Analysis:

“According to SNS Insider, The Bleeding Disorders Treatment Market Size was valued at USD 16.35 billion in 2023 and is expected to attain a valuation of USD 35.17 billion by 2032, at a CAGR of 8.91% between 2024 to 2032.”

The Bleeding Disorders Treatment Market is witnessing substantial growth, fueled by the increasing prevalence of bleeding disorders such as hemophilia, von Willebrand disease, and other rare coagulation disorders, alongside advancements in treatment options and supportive government initiatives.

Get a Sample Report of Bleeding Disorders Treatment Market@

Market analysis

The increasing diagnosis of bleeding disorders, better treatment options, and supportive government policies are driving the expansion. According to the World Federation of Hemophilia (WFH), over 1.1 million people worldwide suffer from hemophilia, with Hemophilia A being the most common type. Emerging treatment modalities, including the deployment of recombinant coagulation factor concentrates and gene therapies, which are changing treatment paradigms, producing durable solutions and better patient outcomes. Additionally, increasing healthcare expenditure and the establishment of specialized treatment centers are enhancing access to care, particularly in developing regions.

Major Players Analysis Listed in this Report are:

• Biogen Inc. (Eloctate, Alprolix)
• CSL Behring (Humate-P, Idelvion)
• Pfizer Inc. (BeneFIX, Xyntha)
• Novo Nordisk A/S (Novoeight, Refixia)
• Grifols S.A. (Alphanate, Fanhdi)
• Bayer AG (Kogenate, Jivi)
• Octapharma AG (Wilate, Nuwiq)
• Sanofi (Altuviiio, Obizur)
• Roche (Hemlibra, ACE910)
• Takeda Pharmaceutical (Advate, Feiba)
• Ferring Pharmaceuticals (Desmopressin, Stimate Nasal Spray)
• Baxter International (Obizur, Rixubis)
• Amgen Inc. (Investigational therapies)
• Alnylam Pharmaceuticals (RNAi-based treatments)
• Bristol-Myers Squibb (Clinical-stage therapies)
• Janssen Pharmaceuticals (Coagulopathy treatments)
• Zydus Lifesciences (Plasma-derived factor concentrates, Generic antifibrinolytics)
• Sun Pharmaceuticals (Tranexamic acid, Desmopressin)
• AbbVie Inc. ( Clotting factor stabilizers, Anticoagulant reversal agents)
• Bausch & Lomb (Hemostatic products, Specialty bleeding management solutions)

Bleeding Disorders Treatment Market Report Scope

Report Attributes	Details
Market Size in 2023	US$ 16.35 billion
Market Size by 2032	US$ 35.17 billion
CAGR	CAGR of 8.91% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Key Regional Coverage	North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)

Segmentation Analysis

By Type

The Hemophilia A segment held the largest share of 55% of total revenue in 2023. Hemophilia A is caused by a deficiency of clotting factor VIII and is the most common type of hemophilia, accounting for approximately 80% of patients with hemophilia. This segment is increasingly being driven by the rising diagnosis rate and the increasing number of advanced treatment alternatives like recombinant factor VIII concentrates. Gene therapies, such as BioMarin Pharmaceutical Inc's Roctavian, that target Hemophilia A are setting the stage to further revolutionize treatment by potentially offering cures. The growing focus on personalized medicine and the development of extended half-life products are also contributing to the segment's expansion.

By Drug Class

The Recombinant Coagulation Factor Concentrates segment held the highest market share of 40% in 2023. Recombinant factors are preferred because they have demonstrated comparable efficacy and safety data to plasma-derived products while dramatically reducing the risk for blood-borne infections. The development of extended half-life recombinant factors, such as Eloctate and Adynovate, has significantly improved patient convenience by reducing the frequency of infusions. The growth of the segment is being projected through these developments, combined with growing adoption in developed region. In addition, the increasing focus on the development of next-generation recombinant products with improved stability and prolonged action is projected to propel the growth of the market.

By End-User

The hospital segment held the largest market share, accounting for 50% of the total revenue earned in 2023. Hospitals remain the primary care centers for bleeding disorder patients due to the availability of advanced diagnostic tools, specialized healthcare professionals, and comprehensive treatment options. Growth in this segment is driven by the rising number of hospitalization for complex bleeding episodes and surgical procedures in hemophilia patients. Furthermore, the growing presence of hemophilia treatment centers (HTCs) inside hospitals, especially in North America and Europe, is improving patient access to specialized treatment. The growing trend of outpatient care and home-based treatment is also influencing the market, with hospitals increasingly offering training and support for home infusion therapies.

Need any customization research on Bleeding Disorders Treatment Market, Enquire Now@

Bleeding Disorders Treatment Market Segments

By Type

• Hemophilia A
• Hemophilia B
• Von Willebrand Disease (vWD)
• Others

By Drug Class

• Plasma Derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrate
• Desmopressin
• Antifibrinolytics
• Fibrin Sealants
• Other bleeding Disorders Treatment

By End-Users

• Hospital
• Clinics
• Research Institutes
• Others

Regional Insights

In 2023, North America dominated the bleeding disorders treatment market, contributing about 40% of the total revenue. The growing market in this region is driven by high prevalence of hemophilia, advanced healthcare infrastructure, and strong government assistance to administer bleeding disorders. According to the Centers for Disease Control and Prevention (CDC), the number of people in the U.S. with hemophilia is about 20,000. Additionally, extensive investments in research and development strengthen the market position of the region according to the presence of significant market players such as Pfizer Inc., Bayer AG, and Takeda Pharmaceutical Company Limited.

In the Asia-Pacific region, the market is anticipated to grow at the fastest pace due to improving healthcare infrastructure, increasing awareness, and rising government initiatives to tackle bleeding disorders. Countries like China, India, and Japan have made substantial investments in healthcare reform and giving people access to sophisticated therapies. For instance, the government of India national health mission (NHM) has initiated many programs to screen and treat rare diseases such as hemophilia. The region's large patient population and untapped market potential present significant growth opportunities.

Recent Developments

• In January 2024, Pfizer Inc. announced a next-generation recombinant factor VIII concentrate with an extended half-life to be launched, providing better patient convenience and outcomes.
• In 2023, BioMarin Pharmaceutical Inc. received EMA approval for its gene therapy, Roctavian, for the treatment of severe Hemophilia A, marking a significant milestone in the market.

Buy a Single-User PDF of Bleeding Disorders Treatment Market Analysis & Outlook Report 2024-2032@

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

5.1 Market Share by Product Type

5.2 Patient Population Statistics

5.3 Treatment Adoption Rates

5.4 Prevalence and Incidence Rates

5.5 Cost of Treatment

5.6 Insurance Coverage and Access

6. Competitive Landscape

7. Bleeding Disorders Treatment Market by Type

8. Bleeding Disorders Treatment Market by Drug Class

9. Bleeding Disorders Treatment Market by End-Users

10. Regional Analysis

11. Company Profiles

12. Use Cases and Best Practices

13. Conclusion

Access Complete Report Details of Bleeding Disorders Treatment Market Analysis & Outlook 2024-2032@

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

MENAFN04032025004107003653ID1109275744